Urquiza P, Lain A, Sanz-Parra A, Moreno J, Bernardo-Seisdedos G, Dubus P, Gonzalez E, Gutierrez-de-Juan V, Garcia S, Erana H, San Juan I, Macias I, Ben Bdira F, Pluta P, Ortega G, Oyarzabal J, Gonzalez-Muniz R, Rodriguez-Cuesta J, Anguita J, Diez E, Blouin JM, de Verneuil H, Mato JM, Richard E, Falcón-Pérez JM, Castilla J, Millet O.
Sci Transl Med 2018 Sep; 10: eaat7467.
ongenital erythropoietic porphyria is a rare autosomal recessive disease produced by deficient activity of uroporphyrinogen III synthase, the fourth enzyme in the heme biosynthetic pathway. The disease affects many organs, can be life-threatening, and currently lacks curative treatments. Inherited mutations most commonly reduce the enzyme’s stability, altering its homeostasis and ultimately blunting intracellular heme production. This results in uroporphyrin by-product accumulation in the body, aggravating associated pathological symptoms such as skin photosensitivity and disfiguring phototoxic cutaneous lesions. We demonstrated that the synthetic marketed antifungal ciclopirox binds to the enzyme, stabilizing it. Ciclopirox targeted the enzyme at an allosteric site distant from the active center and did not affect the enzyme’s catalytic role. The drug restored enzymatic activity in vitro and ex vivo and was able to alleviate most clinical symptoms of congenital erythropoietic porphyria in a genetic mouse model of the disease at subtoxic concentrations. Our findings establish a possible line of therapeutic intervention against congenital erythropoietic porphyria, which is potentially applicable to most of deleterious missense mutations causing this devastating disease.
PubMed: 30232228. Doi: 10.1126/scitranslmed.aat7467.